Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety

Ni, Jingxian; Sun, Hongzan; Chen, Yaoting; Luo, Jun; Wang, Weidong; Jiang, Xiongying; Dong, Chen; Xu, Li

doi:10.1007/s00432-017-2530-3

Cited by 14 publications

(13 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A retrospective study reveals that 10 patients with unresectable sarcoma refractory to systemic chemotherapy receiving DEB-TACE present with a median survival of 21 months, 1- and 2-year OS rate of 90% and 30%, an ORR of 30.0% and a DCR of 70%, and no severe AE is found post-treatment; and the study concludes that DEB-TACE could serve as an optional treatment for unresectable soft tissue sarcoma refractory to conventionally systemic chemotherapy. [ 7 ] In our study, the patients with other cancers presented with an ORR and a DCR both of 80.0%, and a mean OS of 20.3 months, which indicated a satisfactory efficacy of DEB-TACE in these patients. Moreover, the vast majority of the patients with other cancers presented post-embolization syndrome, and only 1 patient had abdominal discomfort post-treatment, which suggested that DEB-TACE might also be tolerable in these patients.…”

Section: Discussionmentioning

confidence: 51%

A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers

Li¹,

Ji²,

Bai³

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 51%

A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers

Li¹,

Ji²,

Bai³

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…Laboratory data revealed no thrombocytopenia, hyperbilirubinemia, hypoleucocytosis, or failure of hepatic or renal functions. TACE causes postembolization syndrome, with localized pain, fever, vomiting, nausea, and fatigue being the commonest adverse events [21]. In our case, only fever and localized pain were noted after several days of TACE.…”

Section: Discussionmentioning

confidence: 62%

Transcatheter arterial chemoembolization improves the resectability of malignant breast phyllodes tumor with angiosarcoma component: a case report

et al. 2019

View full text Add to dashboard Cite

Background A giant phyllodes tumor of the breast is a rare fibroepithelial lesion, and its treatment is controversial. Many case reports have reported performing skin graft reconstruction after tumor excision. Chest wall resection may be required if the tumor has invaded the chest muscle layer. We speculated that transcatheter arterial chemoembolization (TACE) can improve the resectability of malignant phyllodes tumor of the breast without requiring skin grafting. The English literature contains only one case report similar to our experience. Case presentation We report a rare case of a 51-year-old woman who had a giant malignant phyllodes tumor with heterologous sarcomatous differentiation in her right breast. The tumor was 19.43 × 12.98 × 21.47 cm. Whole-body computed tomography (CT) and bone scan did not reveal distant metastasis. Chest magnetic resonance imaging showed chest wall tumor invasion. Considering that skin defects after mastectomy can be extensive, we administered four courses of chemoembolization in the 5 weeks before surgery (30 mg of epirubicin and embozene microspheres [400, 500, and 700 μm]/week). Each process was well tolerated, with no serious complications. Only fever and local pain at the tumor site were noted, and these symptoms resolved with time. The follow-up CT scan showed a 45% reduction in tumor volume. Therefore, simple mastectomy was performed without skin grafting reconstruction. Wound healing was satisfactory, and the patient was discharged 1 week after surgery. Pathological and immunohistochemistry (IHC) findings showed a malignant phyllodes tumor with an angiosarcoma component. Because of tumor invasion of the chest wall, we recommended the patient receive radiotherapy, but she refused. Two months after surgery, recurrence of the malignant phyllodes tumor with right axillary lymph node involvement and lung metastasis was confirmed. Conclusion Initial surgical resection of giant phyllodes tumors is often challenging. For initial presentation with unresectable giant phyllodes tumor, we recommend to perform TACE prior to surgery. In our patient, preoperative TACE was effective and safe. If the tumor has invaded the chest wall, early radiotherapy after surgery may be recommended for preventing recurrence.

show abstract

“…For tumor tissues with large vascular invasion, transcatheter arterial chemoembolization can be used to mix lipiodol with antitumor drugs for injection into the tumor tissue through the large blood vessels. This approach results in tumor vascular occlusion and antitumor effects 45–47. For tumor tissues without large vascular invasion, the drug can be injected into the tumor tissue through a puncture under the guidance of computed tomography 48,49.…”

Section: Discussionmentioning

confidence: 99%

<p>A temperature-sensitive phase-change hydrogel of topotecan achieves a long-term sustained antitumor effect on retinoblastoma cells</p>

Huo¹,

Wang²,

Liu³

et al. 2019

OTT

View full text Add to dashboard Cite

Background Retinoblastoma (Rb) is one of the most common malignancies among children. Following early diagnosis and prompt treatment, the clinical outcome or prognosis of Rb is promising. However, the prognosis or survival rates of patients with late-stage Rb remain poor. Current therapeutic strategies for advanced Rb mainly involve the use of advanced chemotherapeutic options. However, the efficacy of these strategies is not satisfactory. Therefore, the development of novel strategies to achieve a more effective antitumor effect on late-stage Rb is of crucial importance. Methods and materials Topotecan was dissolved in phosphate-buffered saline and prepared into a temperature-sensitive phase-change hydrogel (termed Topo-Gel). Moreover, Topo-Gel was injected into tumor tissues formed by Y79 cells (an Rb cell line) in nude mice to examine the long-term release and long-acting antitumor effect of Topo-Gel on Rb tumors. Results Topo-Gel transforms from liquid to a hydrogel at near body temperatures (phase-change temperature [T 1/2 ] was 37.23±0.473 °C), and maintains the slow release of topotecan in Rb tumor tissues. Following the subcutaneous injection of Topo-Gel, the treatment induced long-acting inhibition of tumor growth and relieved the adverse effects associated with topotecan. Topo-Gel, a temperature-sensitive phase-change hydrogel, is a slow-release system that prolongs the presence of topotecan in Rb tissues, and preserves the efficacy of topotecan in the long term. Conclusion Preparation of topotecan into a temperature-sensitive phase-change hydrogel achieves a long-term sustained antitumor effect on Rb cells, and may be a useful strategy for the treatment of intraocular Rb.

show abstract

Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety

Abstract: Our data showed that DEB-TACE was effective and safe for patients with soft tissue sarcoma. Therefore, DEB-TACE can be considered as an alternative treatment option for unresectable soft tissue sarcoma refractory to conventionally systemic chemotherapy.

Cited by 14 publications

References 30 publications

A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers

A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers

Transcatheter arterial chemoembolization improves the resectability of malignant breast phyllodes tumor with angiosarcoma component: a case report

<p>A temperature-sensitive phase-change hydrogel of topotecan achieves a long-term sustained antitumor effect on retinoblastoma cells</p>

Contact Info

Product

Resources

About